LogicBio Therapeutics (OTCMKTS:LOGC) Shares Gap Down – Should You Sell?

Shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) gapped down prior to trading on Friday. The stock had previously closed at $15.05, but opened at $14.55. LogicBio Therapeutics shares last traded at $14.55, with a volume of 683 shares changing hands.

LogicBio Therapeutics Stock Performance

The company has a 50-day moving average of $11.82 and a 200-day moving average of $9.80. The company has a market cap of $676.69 million, a PE ratio of -20.27 and a beta of 2.11. The company has a quick ratio of 1.24, a current ratio of 1.87 and a debt-to-equity ratio of 0.29.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The company had revenue of $33.60 million during the quarter, compared to analyst estimates of $33.60 million.

About LogicBio Therapeutics

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.